Chinese Journal of Stroke ›› 2025, Vol. 20 ›› Issue (5): 636-646.DOI: 10.3969/j.issn.1673-5765.2025.05.011
Previous Articles Next Articles
Translator: LI Hui1,2, XIE Xuewei1,3
Received:
2025-05-01
Online:
2025-05-20
Published:
2025-05-20
Contact:
XIE Xuewei, E-mail: xueweixie@163.com
译者:李辉1,2,谢雪微1,3
通讯作者:
谢雪微 xueweixie@163.com
CLC Number:
Translator: LI Hui, XIE Xuewei. SPIRIT 2025 Statement: Updated Guideline for Protocols of Randomised Trials[J]. Chinese Journal of Stroke, 2025, 20(5): 636-646.
译者:李辉, 谢雪微. SPIRIT 2025声明:随机试验方案指南更新版[J]. 中国卒中杂志, 2025, 20(5): 636-646.
[1] ALTMAN D G. Better reporting of randomised controlled trials:the CONSORT statement[J]. BMJ,1996,313(7057):570-571. [2] ANONYMOUS. Strengthening the credibility of clinical research[J/OL]. Lancet,2010,375(9722):1225[2025-04-30]. https://doi.org/10.1016/S0140-6736 (10) 60523-5. [3] JONES G,ABBASI K. Trial protocols at the BMJ [J/OL]. BMJ,2004,329(7479):1360[2025-04-30]. https://doi.org/10.1136/bmj.329.7479.1360. [4] LI T J,BOUTRON I,AI-SHAHI SALMAN R,et al. Review and publication of protocol submissions to Trials—what have we learned in 10 years?[J/OL]. Trials,2016,18(1):34[2025-04-30]. https://doi.org/10.1186/s13063-016-1743-0. [5] KRLEZA-JERIĆ K,CHAN A W,DICKERSIN K,et al. Principles for international registration of protocol information and results from human trials of health related interventions:Ottawa statement(part 1)[J]. BMJ,2005,330(7497):956-958. [6] LASSERE M,JOHNSON K. The power of the protocol[J]. Lancet,2002,360(9346):1620-1622. [7] CHAN A W,HRÓBJARTSSON A. Promoting public access to clinical trial protocols:challenges and recommendations[J/OL]. Trials,2018,19(1):116[2025-04-30]. https://doi.org/10.1186/s13063-018-2510-1. [8] ZARIN D A,FAIN K M,DOBBINS H D,et al. 10-year update on study results submitted to ClinicalTrials.gov[J]. N Engl J Med,2019,381(20):1966-1974. [9] GRYAZNOV D,VON NIEDERHÄUSERN B,SPEICH B,et al. Reporting quality of clinical trial protocols:a repeated cross-sectional study about the adherence to SPIRIT recommendations in Switzerland,Canada and Germany(ASPIRE-SCAGE)[J/OL]. BMJ Open,2022,12(5):e053417[2025-04-30]. https://doi.org/10.1136/bmjopen-2021-053417. [10] SPEICH B,ODUTAYO A,PECKHAM N,et al. A longitudinal assessment of trial protocols approved by research ethics committees:the adherance to SPIRIT recommendations in the UK(ASPIRE-UK)study[J/OL]. Trials,2022,23(1):601[2025-04-30]. https://doi.org/10.1186/s13063-022-06516-1. [11] KASENDA B,VON ELM E,YOU J J,et al. Agreements between industry and academia on publication rights:a retrospective study of protocols and publications of randomized clinical trials[J/OL]. PLoS Med,2016,13(6):e1002046[2025-04-30]. https://doi.org/10.1371/journal.pmed.1002046. [12] GETZ K,SMITH Z,BOTTO E,et al. New benchmarks on protocol amendment practices,trends and their impact on clinical trial performance[J]. Ther Innov Regul Sci,2024,58(3):539-548. [13] CHAN A W,TETZLAFF J M,ALTMAN D G,et al. SPIRIT 2013 statement:defining standard protocol items for clinical trials[J]. Ann Intern Med,2013,158(3):200-207. [14] CHAN A W,TETZLAFF J M,GØTZSCHE P C,et al. SPIRIT 2013 explanation and elaboration:guidance for protocols of clinical trials[J/OL]. BMJ,2013,346:e7586[2025-04-30]. https://doi.org/10.1136/bmj.e7586. [15] HOPEWELL S,CHAN A W,COLLINS G S,et al. CONSORT 2025 statement:updated guideline for reporting randomised trials[J/OL]. BMJ,2025,389:e081123[2025-04-30]. https://doi.org/10.1136/bmj-2024-081123. [16] HOPEWELL S,BOUTRON I,CHAN A W,et al. An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials[J]. Nat Med,2022,28(9):1740-1743. [17] TUNN R,BOUTRON I,CHAN A W,et al. Methods used to develop the SPIRIT 2024 and CONSORT 2024 statements[J/OL]. J Clin Epidemiol,2024,169:111309[2025-04-30]. https://doi.org/10.1016/j.jclinepi.2024.111309. [18] MOHER D,SCHULZ K F,SIMERA I,et al. Guidance for developers of health research reporting guidelines[J/OL]. PLoS Med,2010,7(2):e1000217[2025-04-30]. https://doi.org/10.1371/journal.pmed.1000217. [19] NEJSTGAARD C H,BOUTRON I,CHAN A W,et al. A scoping review identifies multiple comments suggesting modifications to SPIRIT 2013 and CONSORT 2010[J/OL]. J Clin Epidemiol,2023,155:48-63[2025-04-30]. https://doi.org/10.1016/j.jclinepi.2023.01.003. [20] ØSTENGAARD L,BARRIENTOS A,BOUTRON I,et al. Development of a topic-specific bibliographic database supporting the updates of SPIRIT 2013 and CONSORT 2010[J/OL]. Cochrane Evid Synth Methods,2024,2(5):e12057[2025-04-30]. https://doi.org/10.1002/cesm.12057. [21] JUNQUEIRA D R,ZORZELA L,GOLDER S,et al. CONSORT harms 2022 statement,explanation,and elaboration:updated guideline for the reporting of harms in randomized trials[J/OL]. J Clin Epidemiol,2023,158:149-165[2025-04-30]. https://doi.org/10.1016/j.jclinepi.2023.04.005. [22] BUTCHER N J,MONSOUR A,MEW E J,et al. Guidelines for reporting outcomes in trial protocols:the SPIRIT-outcomes 2022 extension[J]. JAMA,2022,328(23):2345-2356. [23] BOUTRON I,ALTMAN D G,MOHER D,et al. CONSORT statement for randomized trials of nonpharmacologic treatments:a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts[J]. Ann Intern Med,2017,167(1):40-47. [24] HOFFMANN T C,GLASZIOU P P,BOUTRON I,et al. Better reporting of interventions:template for intervention description and replication(TIDieR)checklist and guide[J/OL]. BMJ,2014,348:g1687[2025-04-30]. https://doi.org/10.1136/bmj.g1687. [25] HRÓBJARTSSON A,BOUTRON I,HOPEWELL S,et al. SPIRIT 2025 explanation and elaboration:updated guideline for protocols of randomised trials[J/OL]. BMJ,2025,389:e081660[2025-04-30]. https://doi.org/10.1136/bmj-2024-081660. [26] BARNES C,BOUTRON I,GIRAUDEAU B,et al. Impact of an online writing aid tool for writing a randomized trial report:the COBWEB(CONSORT-based WEB tool)randomized controlled trial[J/OL]. BMC Med,2015,13:221[2025-04-30]. https://doi.org/10.1186/s12916-015-0460-y. [27] CHAUVIN A,RAVAUD P,MOHER D,et al. Accuracy in detecting inadequate research reporting by early career peer reviewers using an online CONSORT-based peer-review tool(COBPeer)versus the usual peer-review process:a cross-sectional diagnostic study[J/OL]. BMC Med,2019,17(1):205[2025-04-30]. https://doi.org/10.1186/s12916-019-1436-0. [28] PAGE M J,MCKENZIE J E,BOSSUYT P M,et al. The PRISMA 2020 statement:an updated guideline for reporting systematic reviews[J/OL]. Syst Rev,2021,10(1):89[2025-04-30]. https://doi.org/10.1186/s13643-021-01626-4. [29] World Medical Association. World Medical Association Declaration of Helsinki:ethical principles for medical research involving human participants[J]. JAMA,2025,333(1):71-74. [30] GETZ K A,STERGIOPOULOS S,SHORT M,et al. The impact of protocol amendments on clinical trial performance and cost[J]. Ther Innov Regul Sci,2016,50(4):436-441. [31] ORKIN A M,GILL P J,GHERSI D,et al. Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances:the CONSERVE 2021 statement[J]. JAMA,2021,326(3):257-265. [32] CHAN A W,L KARAM G,PYMENTO J,et al. Reporting summary results in clinical trial registries:updated guidance from WHO[J/OL]. Lancet Glob Health,2025,13(4):e759-e768[2025-04-30]. https://doi.org/10.1016/S2214-109X (24) 00514-X. [33] GAMBLE C,KRISHAN A,STOCKEN D,et al. Guidelines for the content of statistical analysis plans in clinical trials[J]. JAMA,2017,318(23):2337-2343. [34] CHAN A W,PELLO A,KITCHEN J,et al. Association of trial registration with reporting of primary outcomes in protocols and publications[J]. JAMA,2017,318(17):1709-1711. [35] KAHAN B C,HALL S S,BELLER E M,et al. Consensus statement for protocols of factorial randomized trials:extension of the SPIRIT 2013 statement[J/OL]. JAMA Netw Open,2023,6(12):e2346121[2025-04-30]. https://doi.org/10.1001/jamanetworkopen.2023.46121. [36] CALVERT M,KYTE D,MERCIECA-BEBBER R,et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols:the SPIRIT-PRO extension[J]. JAMA,2018,319(5):483-494. [37] PORCINO A J,SHAMSEER L,CHAN A W,et al. SPIRIT extension and elaboration for n-of-1 trials:SPENT 2019 checklist[J/OL]. BMJ,2020,368:m122[2025-04-30]. https://doi.org/10.1136/bmj.m122. [38] YAP C,REKOWSKI J,URSINO M,et al. Enhancing quality and impact of early phase dose-finding clinical trial protocols:SPIRIT dose-finding extension(SPIRIT-DEFINE)guidance[J/OL]. BMJ,2023,383:e076386[2025-04-30]. https://doi.org/10.1136/bmj-2023-076386. [39] KENDALL T J,ROBINSON M,BRIERLEY D J,et al. Guidelines for cellular and molecular pathology content in clinical trial protocols:the SPIRIT-path extension[J/OL]. Lancet Oncol,2021,22(10):e435-e445[2025-04-30]. https://doi.org/10.1016/S1470-2045 (21) 00344-2. [40] CRUZ RIVERA S,LIU X X,CHAN A W,et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence:the SPIRIT-AI extension[J]. Nat Med,2020,26(9):1351-1363. [41] DAI L,CHENG C W,TIAN R,et al. Standard protocol items for clinical trials with traditional Chinese medicine 2018:recommendations,explanation and elaboration(SPIRIT-TCM extension 2018)[J]. Chin J Integr Med,2019,25(1):71-79. [42] MANYARA A M,DAVIES P,STEWART D,et al. Reporting of surrogate endpoints in randomised controlled trial protocols(SPIRIT-surrogate):extension checklist with explanation and elaboration[J/OL]. BMJ,2024,386:e078525[2025-04-30]. https://doi.org/10.1136/bmj-2023-078525. [43] BLANCO D,DONADIO M V F,CADELLANS-ARRÓNIZ A. Enhancing reporting through structure:a before and after study on the effectiveness of SPIRIT-based templates to improve the completeness of reporting of randomized controlled trial protocols[J/OL]. Res Integr Peer Rev,2024,9(1):6[2025-04-30]. https://doi.org/10.1186/s41073-024-00147-7. [44] TAN Z W,TAN A C,LI T,et al. Has the reporting quality of published randomised controlled trial protocols improved since the SPIRIT statement?A methodological study[J/OL]. BMJ Open,2020,10(8):e038283[2025-04-30]. https://doi.org/10.1136/bmjopen-2020-038283. [45] RUSS H,BUSTA S,JOST B,et al. Evaluation of clinical trials by Ethics Committees in Germany—results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies(vfa) [J/OL]. Ger Med Sci,2015,13:Doc02[2025-04-30]. https://doi.org/10.3205/000206. [46] TARG Meta-Research Group & Collaborators. Estimating the prevalence of discrepancies between study registrations and publications:a systematic review and meta-analyses[J/OL]. BMJ Open,2023,13(10):e0762642[2025-04-30]. https://doi.org/10.1136/bmjopen-2023-076264. [47] CHAN A W,HRÓBJARTSSON A,HAAHR M T,et al. Empirical evidence for selective reporting of outcomes in randomized trials:comparison of protocols to published articles[J]. JAMA,2004,291(20):2457-2465. [48] SCHÖNENBERGER C M,GRIESSBACH A,TAJI HERAVI A,et al. A meta-research study of randomized controlled trials found infrequent and delayed availability of protocols[J/OL]. J Clin Epidemiol,2022,149:45-52[2025-04-30]. https://doi.org/10.1016/j.jclinepi.2022.05.014. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||